Date: 2017-08-22
Type of
information: Completion of the trial
phase: 1
Announcement: completion of the trial
Company: PharmAkea (USA - CA)
Product: PAT-1251
Action
mechanism: lysyl oxidase type 2 enzyme (LOXL2) inhibitor.
Disease: idiopathic pulmonary fibrosis (IPF), fibrotic diseases
Therapeutic
area: Lung diseases - Respiratory diseases - Rare diseases - Fibrotic diseases
Country: UK
Trial
details:
- This single?center, randomized, placebo?controlled study consisting of both a single ascending dose (SAD) and a multiple ascending dose (MAD) portion is to evaluate the safety, tolerability, pharmacokinetics and effect of food using PAT?1251 orally administered to healthy subjects. (NCT02852551)
Latest
news:
- • On August 22, 2017, PharmAkea announced that it has successfully completed a Phase 1 single and multiple ascending dose clinical study with PAT-1251, its novel, small-molecule LOXL2 inhibitor being developed for the treatment of IPF and other fibrotic diseases. The study results indicate that PAT-1251 was generally well tolerated and a maximum tolerated dose was achieved. A proprietary target engagement assay was used successfully to demonstrate that PAT-1251 binds the LOXL2 enzyme in plasma. After successful completion of the 6- and 9-month toxicology studies in Q4 2017, PAT-1251 will be ready to enter Phase 2 clinical development in early 2018.
Is
general: Yes
